ctDNA predicts outcomes in lung cancer patients receiving radiotherapy

In this peer-to-peer exchange, Aadel Chaudhuri, MD, PhD, and Maximilian Diehn, MD, PhD, both of the Stanford School of Medicine in California, discuss results of a study that tested whether analysing circulating tumour DNA (ctDNA) during treatment with chemo-radiotherapy could predict outcomes in patients with localised lung cancer.
Cancer Network